ES2502790T3 - Aurora kinase modulators and method of use - Google Patents
Aurora kinase modulators and method of use Download PDFInfo
- Publication number
- ES2502790T3 ES2502790T3 ES11008953.9T ES11008953T ES2502790T3 ES 2502790 T3 ES2502790 T3 ES 2502790T3 ES 11008953 T ES11008953 T ES 11008953T ES 2502790 T3 ES2502790 T3 ES 2502790T3
- Authority
- ES
- Spain
- Prior art keywords
- chr15
- independently
- formula
- alkyl
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003989 Aurora kinases Human genes 0.000 title 1
- 108090000433 Aurora kinases Proteins 0.000 title 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 101000869592 Daucus carota Major allergen Dau c 1 Proteins 0.000 abstract 1
- 101000650136 Homo sapiens WAS/WASL-interacting protein family member 3 Proteins 0.000 abstract 1
- 102100027539 WAS/WASL-interacting protein family member 3 Human genes 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pyrane Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compuesto de formula I:**Fórmula** O un estereoisomero, tautórnero, solvato o sal farmaceuticamente aceptable del mismo, en la que cada uno de A1 y A2, independientemente, es N o CR9, siempre que al menos uno de A1 y A2 sea N; C1 es CR16; C2 es N o CH; D es **Fórmula** en los que D4 es NR, 0, S o CR12; D5 es N o CR2; R1 es H, OR 14 , SR 14 , OR 15 , SR 15 , NR 14 R 15 , NR 15 R 15 , (CHR15)nR14, (CHR15)nR15 0 R15, en los que n es 0, 1, 2, 3 0 4; Ria es H, CN o alquilo C1-10; alternativamente R1, tornado junto con Rla y los atomos de carbono o nitrogeno a los que estan unidos, forman un anillo de atomos de carbono parcial o completamente insaturado de 5 0 6 miembros que incluye opcionalmente 1-3 heteroatomos seleccionados de 0, N y S, y estando el anillo opcionalmente sustituido, independientemente, con 1-3 sustituyentes de oxo, R1*, SR14, 0/314, sR15, OR15, OC(0)R15, C00R15, C(0)R15, C(0)NR15R15, NR14R15 o NR 5R15; y R2 es H, halo, NO2, CN, alquilo C1_10 o alcoxilo L1 es NR15, 0, CHR15, S, C(0), S(0) o SO2; L2 es NR15, 0 o S; cada uno de R3, R4 y R9, independientemente, es H;Compound of formula I: ** Formula ** OR a stereoisomer, tautomer, solvate or pharmaceutically acceptable salt thereof, wherein each of A1 and A2, independently, is N or CR9, provided that at least one of A1 and A2 let N; C1 is CR16; C2 is N or CH; D is ** Formula ** where D4 is NR, 0, S or CR12; D5 is N or CR2; R1 is H, OR 14, SR 14, OR 15, SR 15, NR 14 R 15, NR 15 R 15, (CHR15) nR14, (CHR15) nR15 0 R15, where n is 0, 1, 2, 3 0 4; Ria is H, CN, or C1-10 alkyl; alternatively R1, tornado together with Rla and the carbon or nitrogen atoms to which they are attached, form a ring of partially or completely unsaturated 5 0 6-membered carbon atoms optionally including 1-3 heteroatoms selected from 0, N and S , and the ring being optionally substituted, independently, with 1-3 oxo substituents, R1 *, SR14, 0/314, sR15, OR15, OC (0) R15, C00R15, C (0) R15, C (0) NR15R15 , NR14R15 or NR 5R15; and R2 is H, halo, NO2, CN, C1-10 alkyl or L1 alkoxy is NR15, 0, CHR15, S, C (0), S (0) or SO2; L2 is NR15, 0 or S; each of R3, R4 and R9, independently, is H;
Description
Claims (1)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76167506P | 2006-01-23 | 2006-01-23 | |
| US761675P | 2006-01-23 | ||
| US11/655,642 US7560551B2 (en) | 2006-01-23 | 2007-01-18 | Aurora kinase modulators and method of use |
| US655642 | 2007-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2502790T3 true ES2502790T3 (en) | 2014-10-06 |
Family
ID=40849087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11008953.9T Active ES2502790T3 (en) | 2006-01-23 | 2007-01-22 | Aurora kinase modulators and method of use |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1984353B1 (en) |
| JP (2) | JP5280862B2 (en) |
| KR (2) | KR101332975B1 (en) |
| AU (2) | AU2007208351C1 (en) |
| BR (1) | BRPI0706684A2 (en) |
| CA (1) | CA2637658C (en) |
| CR (1) | CR10213A (en) |
| DK (1) | DK1984353T3 (en) |
| EA (1) | EA018128B1 (en) |
| ES (1) | ES2502790T3 (en) |
| GE (1) | GEP20125643B (en) |
| HR (1) | HRP20160039T1 (en) |
| HU (1) | HUE028504T2 (en) |
| IL (1) | IL192812A (en) |
| MA (1) | MA30224B1 (en) |
| MY (1) | MY161884A (en) |
| NO (1) | NO20083639L (en) |
| NZ (1) | NZ569815A (en) |
| TN (1) | TNSN08310A1 (en) |
| WO (1) | WO2007087276A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007208351C1 (en) * | 2006-01-23 | 2011-07-07 | Amgen Inc. | Aurora kinase modulators and method of use |
| US7776857B2 (en) * | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| ES2413806T3 (en) | 2008-03-20 | 2013-07-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| AU2009279760B2 (en) * | 2008-08-04 | 2012-07-12 | Amgen Inc. | Aurora kinase modulators and methods of use |
| US9126935B2 (en) | 2008-08-14 | 2015-09-08 | Amgen Inc. | Aurora kinase modulators and methods of use |
| ES2397934T3 (en) | 2008-12-17 | 2013-03-12 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
| UY32582A (en) | 2009-04-28 | 2010-11-30 | Amgen Inc | 3 KINASE PHOSPHINOSITI INHIBITORS AND / OR MAMMAL OBJECTIVE |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| HUE024568T2 (en) | 2009-09-11 | 2016-02-29 | Amgen Inc | N- (4 - ((3- (2-Amino-4-pyrimidinyl) -2-pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic resistant cancer |
| CN103703000B (en) | 2011-03-23 | 2015-11-25 | 安姆根有限公司 | The fused tricyclic double inhibitor of CDK4/6 and FLT3 |
| US10053452B2 (en) * | 2013-12-03 | 2018-08-21 | Amgen Inc. | Crystalline forms of N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine salts and uses thereof |
| WO2016196771A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders |
| SG11201801856XA (en) | 2015-09-18 | 2018-04-27 | Kaken Pharmaceutical Co Ltd | Biaryl derivative and medicine containing same |
| JP7032903B2 (en) * | 2016-10-12 | 2022-03-09 | 田辺三菱製薬株式会社 | Method for producing a sulfonamide compound |
| US12600726B2 (en) | 2017-07-12 | 2026-04-14 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| CN109384782A (en) * | 2017-08-04 | 2019-02-26 | 厦门大学 | Substituted five-membered and six-membered heterocyclic compound, its preparation method, pharmaceutical combination and use thereof |
| IL310346A (en) | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2020049208A1 (en) | 2018-09-09 | 2020-03-12 | Fundacio Privada Institut De Recerca De La Sida - Caixa | Aurora kinase as target for treating, preventing or curing hiv infection or aids |
| AU2020358000A1 (en) | 2019-10-04 | 2022-04-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| CN112898292A (en) | 2019-12-03 | 2021-06-04 | 微境生物医药科技(上海)有限公司 | Novel aurora kinase inhibitor and use thereof |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| CN111302948A (en) * | 2020-04-13 | 2020-06-19 | 长兴进源新材料科技有限公司 | Synthesis method of 2, 2-bis (4-aminophenyl) hexafluoropropane |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| JP2026505872A (en) * | 2023-02-06 | 2026-02-18 | タイプシックス セラピューティクス，インク． | Compounds, compositions and methods of using them |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001025220A1 (en) * | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
| ATE394102T1 (en) | 2000-06-28 | 2008-05-15 | Astrazeneca Ab | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS AURORA-2-KINASE INHIBITORS |
| US6864255B2 (en) * | 2001-04-11 | 2005-03-08 | Amgen Inc. | Substituted triazinyl amide derivatives and methods of use |
| DE60234125D1 (en) | 2001-12-24 | 2009-12-03 | Astrazeneca Ab | E INHIBITORS |
| JP4469179B2 (en) * | 2002-01-23 | 2010-05-26 | バイエル ファーマセチカル コーポレーション | Pyrimidine derivatives as Rho kinase inhibitors |
| WO2004039774A2 (en) | 2002-05-23 | 2004-05-13 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| GB0219054D0 (en) | 2002-08-15 | 2002-09-25 | Cyclacel Ltd | New purine derivatives |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| FR2853378B1 (en) | 2003-04-02 | 2006-03-10 | Carbone Lorraine Composants | VENTILATED DISK BRAKE PADS |
| CA2553160C (en) * | 2003-12-29 | 2010-09-28 | Banyu Pharmaceutical Co., Ltd. | 2-heteroaryl-substituted benzimidazole derivative |
| EP1751136B1 (en) * | 2004-05-07 | 2014-07-02 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| AU2007208351C1 (en) * | 2006-01-23 | 2011-07-07 | Amgen Inc. | Aurora kinase modulators and method of use |
-
2007
- 2007-01-22 AU AU2007208351A patent/AU2007208351C1/en active Active
- 2007-01-22 WO PCT/US2007/001714 patent/WO2007087276A1/en not_active Ceased
- 2007-01-22 ES ES11008953.9T patent/ES2502790T3/en active Active
- 2007-01-22 HU HUE07716912A patent/HUE028504T2/en unknown
- 2007-01-22 KR KR1020117025676A patent/KR101332975B1/en active Active
- 2007-01-22 NZ NZ569815A patent/NZ569815A/en unknown
- 2007-01-22 EA EA200801732A patent/EA018128B1/en not_active IP Right Cessation
- 2007-01-22 GE GEAP200710871A patent/GEP20125643B/en unknown
- 2007-01-22 JP JP2008551471A patent/JP5280862B2/en active Active
- 2007-01-22 KR KR1020087020677A patent/KR101300424B1/en active Active
- 2007-01-22 HR HRP20160039TT patent/HRP20160039T1/en unknown
- 2007-01-22 EP EP07716912.6A patent/EP1984353B1/en active Active
- 2007-01-22 CA CA2637658A patent/CA2637658C/en active Active
- 2007-01-22 MY MYPI20082661A patent/MY161884A/en unknown
- 2007-01-22 DK DK07716912.6T patent/DK1984353T3/en active
- 2007-01-22 BR BRPI0706684-8A patent/BRPI0706684A2/en not_active IP Right Cessation
-
2008
- 2008-07-14 IL IL192812A patent/IL192812A/en active IP Right Grant
- 2008-07-21 TN TNP2008000310A patent/TNSN08310A1/en unknown
- 2008-08-18 CR CR10213A patent/CR10213A/en unknown
- 2008-08-19 MA MA31184A patent/MA30224B1/en unknown
- 2008-08-22 NO NO20083639A patent/NO20083639L/en not_active Application Discontinuation
-
2010
- 2010-11-05 AU AU2010241280A patent/AU2010241280B2/en active Active
-
2013
- 2013-01-23 JP JP2013010303A patent/JP5753546B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2502790T3 (en) | Aurora kinase modulators and method of use | |
| ES2500068T3 (en) | MEK heterocyclic inhibitors and methods of use thereof | |
| AR057987A1 (en) | CB1 AGONIST COMPOUNDS (CANNABINOID RECEPTOR) | |
| CO6270228A2 (en) | DERIVATIVES OF QUINAZILINONA 6-, 7-, U 8-REPLACED AND COMPOSITIONS THAT UNDERSTAND AND METHODS TO USE THE SAME | |
| ES2570745T3 (en) | Aza-bicyclic heterocycles and their use | |
| ES2222336T3 (en) | SUNFLOWER INHIBITORS AND THEIR USES. | |
| AR052458A1 (en) | AMINO-IMIDAZOLONAS FOR THE INHIBITION OF BETA-SECRETASA | |
| AR055150A1 (en) | ISOINDOL COMPOUNDS - IMIDO AND COMPOSITIONS THAT INCLUDE THEM AND THEIR METHODS OF USE | |
| AR069435A1 (en) | DERIVATIVES OF AMINOTIAZOL, PROCESS FOR OBTAINING THE SAME, PHARMACEUTICAL COMPOSITIONS AND ITS USE AS FBPASA INHIBITORS | |
| AR038536A1 (en) | N-ARIL-2-OXAZOLIDINONA-5- CARBOXAMIDS AND ITS DERIVATIVES | |
| CO5631434A2 (en) | DERIVATIVES OF PIRIDINA-CARBOXAMIDA AND ITS USE AS PESTICIDES | |
| ECSP034865A (en) | OPTICAL RESOLUTION OF (1-BENZILO-4-METHYLOPIPERIDINE-3-IL) -METILAMINE AND ITS USE FOR THE PREPARATION OF PIRROLO DERIVATIVES 2,3-PYRIMIDINE AS PROTEIN KINASE INHIBITORS | |
| AR056327A1 (en) | NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS | |
| AR053994A1 (en) | SULFONYLPIRROLIDINAS REPLACED PROCEDURE FOR PREPARATION AND USE AS MEDICATIONS | |
| AR068054A1 (en) | PIRROLOPIRIMIDINE COMPOUNDS | |
| CO5601027A2 (en) | DERIVATIVES OF IMIDAZOL-4-IL-ETINIL-PIRIDINA | |
| AR041250A1 (en) | SULFONAMIDE DERIVATIVES AS INHIBITORS OF TNF-ALFA CONVERTER ENZYMES | |
| ES2436020T3 (en) | Substituted sulfonamide derivatives | |
| ECSP088479A (en) | DERIVATIVES OF OXADIAZOL | |
| ES2322602T3 (en) | CONDENSED HETEROTETHYCLIC COMPOUNDS AND ITS USE AS AN HCV POLYMERASE INHIBITOR. | |
| EA200300558A1 (en) | AGONISTS OF ALPHA-RECEPTORS ACTIVATED BY PROLIFERATOR PEROXYXOMA | |
| EA200970493A1 (en) | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | |
| AR047817A1 (en) | DERIVATIVES OF ARIL- AND HETEROARILPIPERIDINCARBOXILATOS, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
| HRP20090071T3 (en) | Indole derivatives and use thereof as kinase inhibitors in particular ikk2 inhibitors | |
| AR054481A1 (en) | DERIVATIVES OF 2-AZETIDINONES AS INHIBITORS OF CHOLESTEROL ABSORPTION |